S&P 500   4,532.76 (-0.97%)
DOW   35,028.65 (-0.96%)
QQQ   366.48 (-1.10%)
AAPL   166.23 (-2.10%)
MSFT   303.33 (+0.22%)
FB   319.59 (+0.45%)
GOOGL   2,702.33 (-0.65%)
AMZN   3,125.98 (-1.65%)
TSLA   995.65 (-3.38%)
NVDA   250.67 (-3.23%)
BABA   127.74 (-0.67%)
NIO   28.63 (-3.31%)
AMD   128.27 (-2.77%)
CGC   7.64 (-1.80%)
MU   90.00 (-3.09%)
GE   100.62 (-2.21%)
T   27.28 (-0.11%)
F   22.45 (-7.92%)
DIS   150.11 (-1.42%)
AMC   18.32 (-2.76%)
PFE   53.54 (-1.05%)
ACB   4.86 (-4.89%)
BA   217.08 (-3.52%)
S&P 500   4,532.76 (-0.97%)
DOW   35,028.65 (-0.96%)
QQQ   366.48 (-1.10%)
AAPL   166.23 (-2.10%)
MSFT   303.33 (+0.22%)
FB   319.59 (+0.45%)
GOOGL   2,702.33 (-0.65%)
AMZN   3,125.98 (-1.65%)
TSLA   995.65 (-3.38%)
NVDA   250.67 (-3.23%)
BABA   127.74 (-0.67%)
NIO   28.63 (-3.31%)
AMD   128.27 (-2.77%)
CGC   7.64 (-1.80%)
MU   90.00 (-3.09%)
GE   100.62 (-2.21%)
T   27.28 (-0.11%)
F   22.45 (-7.92%)
DIS   150.11 (-1.42%)
AMC   18.32 (-2.76%)
PFE   53.54 (-1.05%)
ACB   4.86 (-4.89%)
BA   217.08 (-3.52%)
S&P 500   4,532.76 (-0.97%)
DOW   35,028.65 (-0.96%)
QQQ   366.48 (-1.10%)
AAPL   166.23 (-2.10%)
MSFT   303.33 (+0.22%)
FB   319.59 (+0.45%)
GOOGL   2,702.33 (-0.65%)
AMZN   3,125.98 (-1.65%)
TSLA   995.65 (-3.38%)
NVDA   250.67 (-3.23%)
BABA   127.74 (-0.67%)
NIO   28.63 (-3.31%)
AMD   128.27 (-2.77%)
CGC   7.64 (-1.80%)
MU   90.00 (-3.09%)
GE   100.62 (-2.21%)
T   27.28 (-0.11%)
F   22.45 (-7.92%)
DIS   150.11 (-1.42%)
AMC   18.32 (-2.76%)
PFE   53.54 (-1.05%)
ACB   4.86 (-4.89%)
BA   217.08 (-3.52%)
S&P 500   4,532.76 (-0.97%)
DOW   35,028.65 (-0.96%)
QQQ   366.48 (-1.10%)
AAPL   166.23 (-2.10%)
MSFT   303.33 (+0.22%)
FB   319.59 (+0.45%)
GOOGL   2,702.33 (-0.65%)
AMZN   3,125.98 (-1.65%)
TSLA   995.65 (-3.38%)
NVDA   250.67 (-3.23%)
BABA   127.74 (-0.67%)
NIO   28.63 (-3.31%)
AMD   128.27 (-2.77%)
CGC   7.64 (-1.80%)
MU   90.00 (-3.09%)
GE   100.62 (-2.21%)
T   27.28 (-0.11%)
F   22.45 (-7.92%)
DIS   150.11 (-1.42%)
AMC   18.32 (-2.76%)
PFE   53.54 (-1.05%)
ACB   4.86 (-4.89%)
BA   217.08 (-3.52%)
NASDAQ:AFMD

Affimed Stock Forecast, Price & News

$4.26
+0.04 (+0.95%)
(As of 01/19/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.25
$4.42
50-Day Range
$4.22
$7.07
52-Week Range
$4.20
$11.74
Volume
951,226 shs
Average Volume
1.14 million shs
Market Capitalization
$418.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.53
30 days | 90 days | 365 days | Advanced Chart
Receive AFMD News and Ratings via Email

Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter.


Affimed logo

About Affimed

Affimed NV engages in the discovery and development of cancer immunotherapies. It offers ROCK novel proprietary antibody platform, which delivers types of next-generation tetravalent antibody formats, including bispecific and trispecific innate cell engagers. It operates through the following geographical segments: Germany, Europe, and USA. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AFMD
Employees
158
Year Founded
N/A

Sales & Book Value

Annual Sales
$32.39 million
Book Value
$0.84 per share

Profitability

Net Income
$-47.25 million
Net Margins
-132.18%
Pretax Margin
-123.37%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$418.70 million
Optionable
Optionable

Company Calendar

Last Earnings
11/10/2021
Today
1/19/2022
Next Earnings (Estimated)
4/21/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.14 out of 5 stars

Medical Sector

463rd out of 1,415 stocks

Pharmaceutical Preparations Industry

216th out of 682 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Affimed (NASDAQ:AFMD) Frequently Asked Questions

Is Affimed a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Affimed stock.
View analyst ratings for Affimed
or view top-rated stocks.

How has Affimed's stock price been impacted by COVID-19?

Affimed's stock was trading at $1.82 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AFMD stock has increased by 134.1% and is now trading at $4.26.
View which stocks have been most impacted by COVID-19
.

When is Affimed's next earnings date?

Affimed is scheduled to release its next quarterly earnings announcement on Thursday, April 21st 2022.
View our earnings forecast for Affimed
.

How were Affimed's earnings last quarter?

Affimed (NASDAQ:AFMD) posted its quarterly earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.01. The biopharmaceutical company had revenue of $10.21 million for the quarter, compared to analysts' expectations of $11.79 million. Affimed had a negative trailing twelve-month return on equity of 40.23% and a negative net margin of 132.18%. During the same quarter in the prior year, the firm posted ($0.08) earnings per share.
View Affimed's earnings history
.

What price target have analysts set for AFMD?

7 brokers have issued 12 month price targets for Affimed's shares. Their forecasts range from $10.00 to $15.00. On average, they expect Affimed's share price to reach $13.17 in the next twelve months. This suggests a possible upside of 209.1% from the stock's current price.
View analysts' price targets for Affimed
or view top-rated stocks among Wall Street analysts.

Who are Affimed's key executives?

Affimed's management team includes the following people:
  • Adolf Hoess, Chief Executive Officer
  • Wolfgang Fischer, Chief Operating Officer
  • Angus W. Smith, Chief Financial Officer
  • Andreas Harstrick, Chief Medical Officer
  • Arndt Schottelius, Chief Scientific Officer

What other stocks do shareholders of Affimed own?

What is Affimed's stock symbol?

Affimed trades on the NASDAQ under the ticker symbol "AFMD."

Who are Affimed's major shareholders?

Affimed's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Harbor Investment Advisory LLC (0.21%), Lenox Wealth Advisors LLC (0.01%) and Cutler Group LP (0.00%).

Which institutional investors are selling Affimed stock?

AFMD stock was sold by a variety of institutional investors in the last quarter, including Harbor Investment Advisory LLC.

Which institutional investors are buying Affimed stock?

AFMD stock was bought by a variety of institutional investors in the last quarter, including Lenox Wealth Advisors LLC, and Cutler Group LP.

How do I buy shares of Affimed?

Shares of AFMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Affimed's stock price today?

One share of AFMD stock can currently be purchased for approximately $4.26.

How much money does Affimed make?

Affimed has a market capitalization of $418.70 million and generates $32.39 million in revenue each year. The biopharmaceutical company earns $-47.25 million in net income (profit) each year or ($0.55) on an earnings per share basis.

How many employees does Affimed have?

Affimed employs 158 workers across the globe.

What is Affimed's official website?

The official website for Affimed is www.affimed.com.

Where are Affimed's headquarters?

How can I contact Affimed?

Affimed's mailing address is TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The biopharmaceutical company can be reached via phone at 496221674360, via email at [email protected], or via fax at 49-6221-653-0777.


This page was last updated on 1/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.